Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.

[1]  Xuejun Jiang,et al.  E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer , 2023, Oncogene.

[2]  Kebin Hu,et al.  Fibroblast p90RSK induces epithelial transdifferentiation through oxidative stress‐mediated β‐catenin pathway , 2023, Clinical and translational medicine.

[3]  Jinshuai Ma,et al.  Wnt7b/β-catenin signaling pathway mediated by retinoid acid involved in the transdifferentiation of primary fetal alveolar epithelial type II cells. , 2022, General physiology and biophysics.

[4]  Xiaodong Liu,et al.  Host Cell Antimicrobial Responses against Helicobacter pylori Infection: From Biological Aspects to Therapeutic Strategies , 2022, International journal of molecular sciences.

[5]  Mo-pei Wang,et al.  Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy , 2022, Biomarker research.

[6]  Qishan Chen,et al.  The Hippo-YAP pathway in various cardiovascular diseases: Focusing on the inflammatory response , 2022, Frontiers in Immunology.

[7]  K. To,et al.  Recent insight into the role and therapeutic potential of YAP/TAZ in gastrointestinal cancers. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[8]  B. Manavathi,et al.  AMPK: An odyssey of a metabolic regulator, a tumor suppressor, and now a contextual oncogene. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[9]  Liang Ding,et al.  Clinical potential of the Hippo-YAP pathway in bladder cancer , 2022, Frontiers in oncology.

[10]  G. Nicolini,et al.  AMPK and Diseases: State of the Art Regulation by AMPK-Targeting Molecules , 2022, Biology.

[11]  Xiaobo Hu,et al.  Hippo pathway monomerizes STAT3 to regulate prostate cancer growth , 2022, Cancer science.

[12]  Yang Liu,et al.  IDH mutation and cancer stem cell. , 2022, Essays in biochemistry.

[13]  Xifeng Zhang,et al.  Hippo signaling pathway and respiratory diseases , 2022, Cell death discovery.

[14]  Fang Hao.  An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango , 2022, Clinical and Translational Oncology.

[15]  Zhan‐Qing Yang,et al.  TAZ ameliorates the microglia-mediated inflammatory response via the Nrf2-ROS-NF-κB pathway , 2022, Molecular therapy. Nucleic acids.

[16]  A. Matheu,et al.  Impact of Cancer Stem Cells on Therapy Resistance in Gastric Cancer , 2022, Cancers.

[17]  W. El-Rifai,et al.  Helicobacter pylori-induced RASAL2 through activation of NF-kB promotes gastric tumorigenesis via β-catenin signaling axis. , 2022, Gastroenterology.

[18]  C. G. Hansen,et al.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer , 2022, Clinical science.

[19]  M. Kanchwala,et al.  YAP/TAZ drives cell proliferation and tumor growth via a polyamine-eIF5A hypusination-LSD1 axis , 2022, Nature Cell Biology.

[20]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[21]  H. Cai,et al.  YAP Overexpression in Breast Cancer Cells Promotes Angiogenesis through Activating YAP Signaling in Vascular Endothelial Cells , 2020, Analytical cellular pathology.

[22]  Milagros Rojas,et al.  The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises , 2021, International journal of molecular sciences.

[23]  H. Augustin,et al.  STAT3-YAP/TAZ signaling in endothelial cells promotes tumor angiogenesis , 2021, Science Signaling.

[24]  Xiaofeng He,et al.  H. pylori CagA activates the NLRP3 inflammasome to promote gastric cancer cell migration and invasion , 2021, Inflammation Research.

[25]  M. Karamouzis,et al.  YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango , 2021, Biomedicines.

[26]  U. Ghoshal,et al.  Helicobacter pylori-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer , 2021, Pathogens.

[27]  C. Maldonado-Bernal,et al.  Helicobacter pylori; a Way to Gastric Cancer? , 2021, Helicobacter pylori - From First Isolation to 2021.

[28]  H. Isomoto,et al.  Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner , 2021, Oncology letters.

[29]  Lei Wu,et al.  Inflammation and tumor progression: signaling pathways and targeted intervention , 2021, Signal Transduction and Targeted Therapy.

[30]  N. Kim,et al.  Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer , 2021, Cancers.

[31]  Md Soriful Islam,et al.  Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids , 2021, Clinical and translational medicine.

[32]  L. Prézeau,et al.  G protein‐coupled receptors can control the Hippo/YAP pathway through Gq signaling , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. A. C. Smith,et al.  Increased expression of interleukin-6 gene in gastritis and gastric cancer , 2021, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[34]  Hyeyoung Kim,et al.  β-Carotene Inhibits Expression of Matrix Metalloproteinase-10 and Invasion in Helicobacter pylori-Infected Gastric Epithelial Cells , 2021, Molecules.

[35]  P. Guichet,et al.  Hippo Signaling Pathway in Gliomas , 2021, Cells.

[36]  P. Portincasa,et al.  Helicobacter pylori Virulence Factors—Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment , 2020, Cells.

[37]  K. Guan,et al.  Hippo Signaling in Embryogenesis and Development. , 2020, Trends in biochemical sciences.

[38]  A. Azmi,et al.  Gastric cancer: a comprehensive review of current and future treatment strategies , 2020, Cancer and Metastasis Reviews.

[39]  Xiaolong Yang,et al.  Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis , 2020, Cancers.

[40]  N. Yamaguchi.  Multiple Roles of Vestigial-Like Family Members in Tumor Development , 2020, Frontiers in Oncology.

[41]  K. Irvine,et al.  Integration of Hippo-YAP Signaling with Metabolism. , 2020, Developmental cell.

[42]  Zengqiang Yuan,et al.  Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer. , 2020, Cancer cell.

[43]  F. Mégraud,et al.  TAZ Controls Helicobacter pylori-Induced Epithelial–Mesenchymal Transition and Cancer Stem Cell-Like Invasive and Tumorigenic Properties , 2020, Cells.

[44]  S. Hanash,et al.  YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition , 2020, Gut.

[45]  Jun Yu,et al.  AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis , 2020, Oncogene.

[46]  Juan Li,et al.  Metformin suppresses proliferation and invasion of drug‐resistant breast cancer cells by activation of the Hippo pathway , 2020, Journal of cellular and molecular medicine.

[47]  Qi Wang,et al.  Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation , 2020, Cancer medicine.

[48]  Qiu-lin Tang,et al.  Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling , 2020, OncoTargets and therapy.

[49]  A. Pobbati,et al.  A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy , 2020, Theranostics.

[50]  Juan Ye,et al.  Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis , 2020, Cancer Cell International.

[51]  Wei Zhou,et al.  MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway , 2020, Oncogenesis.

[52]  S. Dupont,et al.  YAP/TAZ functions and their regulation at a glance , 2020, Journal of Cell Science.

[53]  Qiaojun He,et al.  Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer , 2019, Acta pharmaceutica Sinica. B.

[54]  F. Mégraud,et al.  Verteporfin targeting YAP1/TAZ‐TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells , 2020, International journal of cancer.

[55]  Michael A. Flinn,et al.  Upstream regulation of the Hippo-Yap pathway in cardiomyocyte regeneration. , 2020, Seminars in cell & developmental biology.

[56]  Zhigang Jin,et al.  The Hippo Pathway and Viral Infections , 2020, Frontiers in Microbiology.

[57]  K. Guan,et al.  STRIPAK integrates upstream signals to initiate the Hippo kinase cascade , 2019, Nature Cell Biology.

[58]  G. Church,et al.  Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. , 2019, Cancer discovery.

[59]  I. Okan,et al.  Significance of Gastric Wall Thickening Detected in Abdominal CT Scan to Predict Gastric Malignancy , 2019, Journal of oncology.

[60]  F. Mégraud,et al.  The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa , 2019, Cellular and molecular gastroenterology and hepatology.

[61]  N. Lu,et al.  The Hippo and Wnt signalling pathways: crosstalk during neoplastic progression in gastrointestinal tissue , 2019, The FEBS journal.

[62]  N. Raj,et al.  Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer , 2019, Front. Cell Dev. Biol..

[63]  K. Guan,et al.  The Hippo Pathway: Biology and Pathophysiology. , 2019, Annual review of biochemistry.

[64]  Zhongxin Lu,et al.  miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway , 2019, Oxidative medicine and cellular longevity.

[65]  B. Goh,et al.  FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway , 2019, Cancers.

[66]  Yujiao Wu,et al.  Helicobacter pylori‐induced YAP1 nuclear translocation promotes gastric carcinogenesis by enhancing IL‐1β expression , 2019, Cancer medicine.

[67]  Tianlun Yang,et al.  Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling. , 2019, Biochemical and biophysical research communications.

[68]  Chunling Yi,et al.  YAP/TAZ Signaling and Resistance to Cancer Therapy. , 2019, Trends in cancer.

[69]  W. Hong,et al.  Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis , 2019, Front. Cell Dev. Biol..

[70]  Bokyung Ahn,et al.  High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer. , 2019, Pathology.

[71]  F. Di Cunto,et al.  Citron kinase interacts with LATS2 and inhibits its activity by occluding its hydrophobic phosphorylation motif , 2019, Journal of molecular cell biology.

[72]  J. Han,et al.  Immune Cell Types and Secreted Factors Contributing to Inflammation-to-Cancer Transition and Immune Therapy Response. , 2019, Cell reports.

[73]  M. Stein,et al.  Inhibition of polarity-regulating kinase PAR1b contributes to Helicobacter pylori inflicted DNA Double Strand Breaks in gastric cells , 2019, Cell cycle.

[74]  Jiing-Dwan Lee,et al.  Verteporfin blocks Clusterin which is required for survival of gastric cancer stem cell by modulating HSP90 function , 2019, International journal of biological sciences.

[75]  S. Bae,et al.  Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway , 2020, Small GTPases.

[76]  L. Ansaloni,et al.  Advanced gastric cancer: the value of surgery , 2018, Acta bio-medica : Atenei Parmensis.

[77]  K. Irvine,et al.  The Hippo Signaling Network and Its Biological Functions. , 2018, Annual review of genetics.

[78]  Zhijun Luo,et al.  Helicobacter pylori CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway , 2018, Journal of Experimental & Clinical Cancer Research.

[79]  D. McCollum,et al.  Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling , 2018, The Journal of Biological Chemistry.

[80]  Y. Huang,et al.  Matrix stiffness mediates stemness characteristics via activating the Yes‐associated protein in colorectal cancer cells , 2018, Journal of cellular biochemistry.

[81]  Liang Sun,et al.  Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[82]  Lin Fang,et al.  VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs. , 2018, American journal of cancer research.

[83]  G. Halder,et al.  Cell Junctions in Hippo Signaling. , 2018, Cold Spring Harbor perspectives in biology.

[84]  D. Gough,et al.  STAT3: a multifaceted oncoprotein , 2018, Growth factors.

[85]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[86]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[87]  Zhiyang Xie,et al.  Dysregulation of YAP by the Hippo pathway is involved in intervertebral disc degeneration, cell contact inhibition, and cell senescence , 2017, Oncotarget.

[88]  Yaopan Mao,et al.  Role and regulation of Yap in KrasG12D-induced lung cancer , 2017, Oncotarget.

[89]  J. Ajani,et al.  A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma , 2017, Molecular Cancer Therapeutics.

[90]  Jianqiu Zhao,et al.  Helicobacter pylori modulates cyclooxygenase-2 and 15-hydroxy prostaglandin dehydrogenase in gastric cancer. , 2017, Oncology letters.

[91]  G. S. Jeong,et al.  Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 , 2017, Oncotarget.

[92]  F. Mégraud,et al.  Metformin targets gastric cancer stem cells. , 2017, European journal of cancer.

[93]  S. Piccolo,et al.  Mechanobiology of YAP and TAZ in physiology and disease , 2017, Nature Reviews Molecular Cell Biology.

[94]  M. Oldham,et al.  An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice. , 2017, Cell stem cell.

[95]  Shao-Cong Sun,et al.  The non-canonical NF-κB pathway in immunity and inflammation , 2017, Nature Reviews Immunology.

[96]  Yuanyu Wu,et al.  Progress in the treatment of advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[97]  B. Carneiro,et al.  Wnt/beta-catenin pathway: modulating anticancer immune response , 2017, Journal of Hematology & Oncology.

[98]  J. Kissil,et al.  Regulation of localization and function of the transcriptional co-activator YAP by angiomotin , 2017, eLife.

[99]  O. Sokolova,et al.  NF-κB Signaling in Gastric Cancer , 2017, Toxins.

[100]  Jun Zhu,et al.  YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma , 2017, Oncotarget.

[101]  D. Hwang,et al.  Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice. , 2017, Gastroenterology.

[102]  K. Guan,et al.  Osmotic stress‐induced phosphorylation by NLK at Ser128 activates YAP , 2017, EMBO reports.

[103]  D. Dumitrascu,et al.  Helicobacter pylori Infection, Gastric Cancer and Gastropanel , 2016, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[104]  N. Lu,et al.  p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? , 2016, Oncotarget.

[105]  M. Sudol,et al.  RUNX3 is a novel negative regulator of oncogenic TEAD–YAP complex in gastric cancer , 2016, Oncogene.

[106]  Julia B. Cordero,et al.  Integrin signalling regulates YAP and TAZ to control skin homeostasis , 2016, Development.

[107]  N. Lu,et al.  Helicobacter pylori Infection Synergistic with IL-1β Gene Polymorphisms Potentially Contributes to the Carcinogenesis of Gastric Cancer , 2016, International journal of medical sciences.

[108]  Markus M. Rinschen,et al.  Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ)* , 2016, The Journal of Biological Chemistry.

[109]  A. Rashid,et al.  Interleukin-1β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. , 2016, Oncology letters.

[110]  Wei Zhao,et al.  Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development , 2016, Oncotarget.

[111]  S. Bicciato,et al.  YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.

[112]  Kun-Liang Guan,et al.  Mechanisms of Hippo pathway regulation , 2016, Genes & development.

[113]  G. Mills,et al.  Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. , 2016, American journal of cancer research.

[114]  Xiao Han,et al.  Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. , 2015, Structure.

[115]  A. Giraud,et al.  STAT3: a critical component in the response to Helicobacter pylori infection , 2015, Cellular microbiology.

[116]  Domenico Beneventano,et al.  MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells , 2015, Oncotarget.

[117]  B. Győrffy,et al.  Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1 , 2015, Science Signaling.

[118]  H. Cortez‐Pinto,et al.  Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[119]  T. Goi,et al.  PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway , 2015, Oncotarget.

[120]  K. Guan,et al.  YAP and TAZ: a nexus for Hippo signaling and beyond. , 2015, Trends in cell biology.

[121]  Wanhu Li,et al.  miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. , 2015, Biochemical and biophysical research communications.

[122]  John T. Chang,et al.  A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.

[123]  J. Luk,et al.  Targeting Hippo pathway by specific interruption of YAP‐TEAD interaction using cyclic YAP‐like peptides , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  K. Guan,et al.  Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.

[125]  J. Asara,et al.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.

[126]  Stephen Fox,et al.  Role of p53 in the progression of gastric cancer , 2014, Oncotarget.

[127]  D. Graham,et al.  Helicobacter pylori Infection Introduces DNA Double-Strand Breaks in Host Cells , 2014, Infection and Immunity.

[128]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.

[129]  Joan W. Miller,et al.  The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. , 2014, Experimental eye research.

[130]  W. Meng,et al.  Helicobacter pylori-induced gastric inflammation and gastric cancer. , 2014, Cancer letters.

[131]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[132]  R. Rosell,et al.  TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma , 2014, BioMed research international.

[133]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[134]  M. Karin,et al.  IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. , 2014, Seminars in immunology.

[135]  Guangxi Zhou,et al.  Effects of the hippo signaling pathway in human gastric cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[136]  Y. Fujii,et al.  YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. , 2013, Developmental cell.

[137]  Kazuhiro Chida,et al.  Polarity-Dependent Distribution of Angiomotin Localizes Hippo Signaling in Preimplantation Embryos , 2013, Current Biology.

[138]  Siddharth Singh,et al.  Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  Robert P. Jenkins,et al.  Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts , 2013, Nature Cell Biology.

[140]  J. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2013, Cell.

[141]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[142]  S. Bae,et al.  Phosphorylation of the gastric tumor suppressor RUNX3 following H. pylori infection results in its localization to the cytoplasm , 2012, Journal of cellular physiology.

[143]  Chun-Yuh Yang,et al.  Statins Are Associated With a Reduced Risk of Gastric Cancer: A Population-Based Case–Control Study , 2011, The American Journal of Gastroenterology.

[144]  R. Fehon,et al.  Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. , 2011, Developmental cell.

[145]  M. Lopes,et al.  Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells , 2011, Proceedings of the National Academy of Sciences.

[146]  Nicola Elvassore,et al.  Role of YAP/TAZ in mechanotransduction , 2011, Nature.

[147]  G. M. Rudakova,et al.  α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1 , 2011, Science Signaling.

[148]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[149]  A. Maitra,et al.  The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. , 2010, Genes & development.

[150]  Jing Wu,et al.  LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling , 2010, Proceedings of the National Academy of Sciences.

[151]  R. Peek,et al.  Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation , 2010, Oncogene.

[152]  J. Vandekerckhove,et al.  TAZ interacts with zonula occludens‐1 and ‐2 proteins in a PDZ‐1 dependent manner , 2010, FEBS letters.

[153]  Zhengyu Zha,et al.  The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.

[154]  R. Peek,et al.  Helicobacter pylori: gastric cancer and beyond , 2010, Nature Reviews Cancer.

[155]  K. Guan,et al.  A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.

[156]  E. Kremmer,et al.  Helicobacter pylori Induces MAPK Phosphorylation and AP-1 Activation via a NOD1-Dependent Mechanism1 , 2009, The Journal of Immunology.

[157]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[158]  C. Sasakawa,et al.  Helicobacter pylori CagA phosphorylation-independent function in epithelial proliferation and inflammation. , 2009, Cell host & microbe.

[159]  H. Aburatani,et al.  Helicobacter pylori CagA interacts with E-cadherin and deregulates the β-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells , 2007, Oncogene.

[160]  C. Obuse,et al.  Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity , 2007, Nature.

[161]  J. Avruch,et al.  Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. , 2004, The Biochemical journal.

[162]  S. Falkow,et al.  Disruption of the Epithelial Apical-Junctional Complex by Helicobacter pylori CagA , 2003, Science.

[163]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[164]  E. Fishman,et al.  Helicobacter pylori gastritis mimicking gastric carcinoma at CT evaluation. , 1991, Radiology.